THE US Food and Drug
Administration (FDA) has slapped
a boxed warning on the labelling
requirements for fluoroquinolone
antibacterial drugs for systemic
use on the basis that the drug
is associated with disabling and
potentially permanent side effects
of the tendons, muscles, joints,
nerves, and central nervous system
that can occur together in the same
patient.
As a result, clinicians will only be
able to prescribe fluoroquinolones
for use in patients who have no
other treatment options for acute
bacterial sinusitis, acute bacterial
exacerbation of chronic bronchitis
and uncomplicated urinary tract
infections because the risk of
these serious side effects generally
outweighs the benefits in these
patients.
For details see www.fda.gov.The above article was sent to subscribers in Pharmacy Daily's issue from 27 Jul 16 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 27 Jul 16
PEAK pharmacy bodies are calling on the Australian Government to extend the new Commonwealth Prac Payment to pharmacy students, citing the challenges of “placement poverty” in unpaid practical placements.
AFT Pharmaceuticals is set to develop a topical treatment for keloid and hypertrophic scarring in partnership with NZ’s Massey Ventures, the commercialisation arm of Massey University, and the Gillies McIndoe Research Institute.
THE Pharmaceutical Society of Australia (PSA) awarded Brooke Shelly the prestigious 2024 PSA MIMS Credentialed Pharmacist of the Year award last Fri at the Credentialed Pharmacist Conference (CPC24) (PD breaking news).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.